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DOI 10.1186/s13028-015-0110-6RESEARCH Open AccessAn international multi-centre prospective study
on the efficacy of an intraarticular polyacrylamide
hydrogel in horses with osteoarthritis: a 24 months
follow-up
Aziz Tnibar1*, Hans Schougaard2, Linus Camitz3, Jonas Rasmussen4, Marc Koene5, Werner Jahn6 and Bo Markussen7Abstract
Background: Polyacrylamide hydrogel (PAAG) was evaluated recently to treat osteoarthritis (OA) in horses with
highly encouraging results; however no long term field-study was done to explore its clinical efficacy and lasting
effect. The objective of this study was to evaluate the efficacy of PAAG in improving clinical signs of OA in horses.
We hypothesized that lameness grade would significantly improve and the effect would last at least 2 years in
osteoarthritic joints treated with PAAG. Forty three horses older than 2 years with OA in only one joint based on
clinical evaluation, intra-articular anaesthesia and imaging (radiography) were included in this study. Horses were
injected with 2 ml of PAAG into the affected joint and were followed up at 1, 3, 6, 12 and 24 months. Efficacy of
PAAG was evaluated by blinded clinical assessment of lameness. Adverse reactions to joint injection were
assessed. Data relating to case details, type of activity, joint and limb involved, lameness duration, lameness
grading, previous joint treatment, joint effusion grading, radiographic grading, and owner assessment were
recorded. Factors associated with the outcome measure “lameness grading” were analyzed using generalized
linear mixed model for logistic regression.
Results: At 1, 3, 6, 12 and 24 months follow-up, 59%, 69%, 79%, 81/% and 82.5% of horses were non-lame
respectively. Reduction of joint effusion was observed over time. No side effect was observed in the treated
joints. There was a significant decrease in lameness grade from baseline to 1, 3, 6, 12 and 24 months (P < 0.0001)
and a significant positive association with joint effusion (P < 0.0001). Estimates for odds ratio (OR) showed that
the effect of treatment increased over time (OR for lower lameness from month 1 to month 24 relative to
baseline increased from 20 to 58).
Conclusions: PAAG significantly alleviated lameness and joint effusion in osteoarthritic joints. PAAG is a safe and
lasting (at least 24 months) OA treatment in horses. PAAG is a promising new treatment for OA in horses.
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Osteoarthritis (OA) is a common clinical problem in
horses [1,2] and is the most common joint disease and
one of the most frequent causes of physical impairment
in humans [3]. Surveys estimate that up to 60% of lame-
ness problems in horses are related to OA [1], which
can occur early in the equine athlete’s career or later in
older horses [4]. The fetlock (metacarpo(tarso)phalan-
geal) joint is a common joint for spontaneous OA in
horses [5].
As part of the OA-complex, elastoviscosity of the syn-
ovial fluid is abnormally low [6], and thus the use of
visco-supplementation, for example intra-articular injec-
tions of high molecular-weight sodium hyaluronan (SH),
has been implemented as part of the treatment for OA
in humans [7,8], and horses [9].
Polyacrylamide hydrogel a (PAAG) is a non-toxic and
non-immunogenic biocompatible polymer gel consisting
of 97.5% sterile water and 2.5% cross-linked polyacryl-
amide [10,11]. Its biocompatibility in soft tissues (e.g. re-
constructive surgery, urology) has been demonstrated
[12-14]. Also, PAAG is a non-particulate homogenous
gel similar to SH gel in overall structure and tissue com-
patibility [13], but with a longer-lasting viscous effect, as
it is non-degradable [10]. This gel has been used for
years in the augmentation of connective tissue in human
medicine [14,15]. Experimental studies supported by
histopathological observations have shown that PAAG
exerts its effect via integration over time within the soft
tissues, through a combination of vessel in-growth and
molecular water exchange [10,13]. A recent clinical study
investigated the effect of PAAG on improving clinical
signs of equine OA within the metacarpo(tarso)phalangeal
joint or one of the carpal joints (antebrachiocarpal, middle
carpal or carpometacarpal) [16]. Thirty-three horses, older
than two years with OA located within only one joint were
treated intra-articularly with PAAG. At 1, 3, and 6 months
after treatment, 81%, 88% and 87% respectively of horses
showed improvement in lameness grade compared with
baseline. At 6 months, approximately 70% of horses were
non-lame [16]. At 12 months, 81% of the horses from the
same study population were non-lame [17]. A recent pilot
study using an experimental OA model in goats has
shown that PAAG was integrated into the synovial mem-
branes of the injected joint, and significantly improved the
lameness caused by OA, with 75% (3 out of 4) of the cases
becoming non-lame at 4 months post treatment evalu-
ation [18]. A comparative prospective study has demon-
strated that horses with OA treated with PAAG
significantly improved their clinical signs when compared
to horses with OA treated with triamcinolone acetonide
combined with SH [19]. Another report has shown that
PAAG effectively relieved lameness in horses with distal
interphalangeal joint OA [20].The purpose of this two year prospective clinical study
was to investigate the efficacy and duration of action of
PAAG for improving clinical signs of OA in the equine
metacarpo(tarso)phalangeal or one of the carpal joints.
Our hypothesis was that lameness scores would signifi-
cantly improve and the effect will last at least 2 years in
osteoarthritic joints after treatment with PAAG.Methods
The clinical study was conducted between October 2010
and February 2014 at 5 major equine hospitals (3 in
Denmark, 2 in Germany). The study was approved by
the National Council for Animal Experimentation
(Authorization number: 2010/561-1890). All horse
owners gave written informed consent. Client-owned
horses older than 2 years with OA confirmed clinically
within a single joint (metacarpo(tarso)phalangeal joint or
one of the carpal joints (antebrachiocarpal, middle carpal
or carpometacarpal)) were included in this clinical study.
The confirmation of OA was based on clinical evalu-
ation, lameness abolished after intra-articular anesthesia
(10 ml of local anesthetic per joint, horses reexamined
in 10 min) and imaging (radiography). Lame horses with
severe radiographic abnormalities were also included in
the study. Exclusion criteria in this study were horses
with lameness problems localized in more than one
joint, horses with OA secondary to joint infection,
horses that had undergone surgery of this joint (includ-
ing arthroscopy) within three months preceding the
study, and horses with any other anti-arthritic treatment
(e.g. nonsteroidal antiinflammatory drugs, corticoste-
roids, SH) administered to the affected joint within two
months preceding the study. Other exclusion criteria in-
cluded horses that had received any additional anti-
arthritic treatment, or undergone surgery during the
study period.
The study was designed as a prospective clinical study.
This study incorporated horses described in previous re-
ports [16,17]. At baseline (day 0), horses were injected
with 2 ml of PAAG into the affected joint. In all cases,
this injection was performed the same day as the intraar-
ticular anesthesia. After treatment, horses were rested
for the first two weeks with only 10 to 15 minutes hand
walking exercise per day, then for the subsequent two
weeks, all horses were allowed hand walking exercise for
20 to 30 minutes per day or turnout in a small paddock.
All horses were clinically assessed under similar circum-
stances by clinicians (one per center) different from the
one who had originally examined and treated the horse,
and unaware of the identity of the horse and whether
joints were treated or not at 1, 3, 6, 12 and 24 months
post-treatment. All horses received only one injection of
PAAG during the study.
Table 1 Variables included in the statistical analysis of
the study population of 43 horses with osteoarthritis of a
metacarpo(tarso)phalangeal joint or carpal joint treated
by intra-articular administration of a polyacrylamide
hydrogel
Variables
- Horse 43
- Sex Female, male, gelding
- Breed Warmblood, racing breed,
others
- Type of activity Dressage, jumping, racing,
others
- Time point (months) 0, 1, 3, 6, 12, 24
- Joint Metacarpo(tarso)phalangeal,
carpus
- Limb involved Front, Hind
- Lameness duration before treatment
(months)
1 to 6, > 6
- Previous treatment Yes, No, Unknown
- Radiographic grading of OA 0 to 3
- Joint effusion grading 0 to 4
- Lameness grading 0 to 5
OA: osteoarthritis.
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examination of the affected joint, including response to
flexion tests. Each horse underwent lower limb (interpha-
langeal and metacarpo(tarso)phalangeal joints) and carpal
flexion tests for 1 min for all limbs. Horses were evaluated
in hand on a hard surface in straight lines and in circles.
Data relating to case details, including type of activity, limb
involved, lameness duration (1–6 months, >6 months), pre-
vious joint treatment (yes (type, duration); no), and lame-
ness grade was collected at baseline. Lameness grading [21]
was performed at baseline, and at 1, 3, 6, 12 and 24 months.
Joint effusion grading (0: no distension, 1: mild, 2: moder-
ate, 3: marked and 4: severe) was only visually assessed at
baseline and at 1, 3, 6, 12 and 24 months. The radiographic
grading of OA was based on standard radiographic projec-
tions [22] for each joint (0: no lesion, 1: mild, 2: moderate
and 3: marked) at baseline only. The radiographic grading
system used was described previously [23] and was used by
a clinician experienced in radiography. The owner’s assess-
ment of the result of the treatment (1: not satisfied, 2:
slightly satisfied, 3: satisfied and 4: very satisfied) was re-
corded at 1, 3, 6, 12 and 24 months. Safety of the joint
treatment was evaluated through recording of any adverse
reaction following joint injection. If the horse was non-
lame one month after post treatment, then the horse was
allowed to progressively resume its normal activity.
Statistical analysis
The statistical variables used in this study are described
in Table 1. Variables potentially associated with the out-
come measure “lameness grading” were analyzed using a
generalized linear mixed model for ordinal regression
with horse identification specified as a random effect.
The initial model consisting of all main effects was re-
duced by backward model selection sequentially remov-
ing non-significant effects on a 5% significance level. To
investigate the development of joint effusion a similar
analysis was done using “effusion grading” as outcome.
This analysis was done without including “lameness
grading” as explanatory variable. The statistical analysis
was done using SAS V9.4.
Results
A total of 43 horses met the inclusion criteria for this
study. Only 41, 26 and 40 horses were examined at
months 1, 3 and 24 respectively. Table 2 summarizes the
descriptive data of the study population. At baseline, the
proportion of horses with a moderate to marked radio-
graphic grade was 47%, whereas 53% of horses had mild
radiographic grade.
Lameness changes in relation to baseline lameness
score. Before treatment (baseline), the proportion of
horses with lameness grade 1, 2, 3 and 4 were 26%, 32%,
35% and 7% respectively. In horses with baselinelameness grade 1 (n = 11), 73% were non-lame at
1 month, and 60 to 82% were non-lame at the following
controls (3, 6, 12 and 24 months). In these horses, 1 out
of 6, 2 out of 11 and 3 out of 10 showed a worsening in
lameness grade at 3, 12 and 24 months respectively, after
a previous lameness improvement. In horses with base-
line lameness grade 2 (n = 14), 62% were non-lame at
1 month, and 79 to 100% were non-lame at the follow-
ing controls (3, 6, 12 and 24 months). In horses with
baseline lameness grade 3 (n = 15), 50% and 62% were
non-lame at 1 and 3 months respectively, whereas 80 to
87% were non-lame at the following controls (6, 12 and
24 months). In horses with baseline lameness grade 4 (n =
3), at 1, 3 and 6 months, only 1 horse was non-lame and 2
other horses were non-lame at 12 and 24 months. No
lameness worsening was observed in horses with baseline
grade 2, 3 and 4.
There was a significant increase in the proportion of
non-lame horses between baseline and 1 month,
followed by a steady increase between 3 and 6 months,
then a stabilization in the proportion of non-lame horses
between 6 and 24 months (Figure 1). Concerning the
outcome, at 1, 3, 6, 12 and 24 months follow-up, irre-
spective of the baseline lameness grade, 59%, 69%, 79%,
81/% and 82.5% of horses were non-lame respectively.
Figure 2 shows the distribution of the change in lame-
ness grades for the individual horses over the observed
time periods. The largest reduction in lameness took
place between baseline and 1 month follow-up. After 1,
Table 2 Description of the study population of 43 horses
with osteoarthritis of a metacarpo(tarso)phalangeal joint
or carpal joint treated by intra-articular administration of
a polyacrylamide hydrogel and variables evaluated
during a 24 months follow-up
Variable Data
Horses (no.) 43
Mean (range) age (years) 9.4 (2–15)
Breeds (no. (%))
Warmbloods 30 (70%)
Racing breeds 8 (19%)
Others 5 (11%)
Horse activity (no. (%))
Dressage 15 (35%)
Jumping 13 (30%)
Racing 8 (19%)
Other 7 (16%)
Limb involved (no. (%))
Front 27 (63%)
Hind 16 (27%)
Joint involved (no. (%))
Metacarpo(metatarso)phalangeal 40 (93%)
Antebrachiocarpal, Middle carpal, Carpometacarpal 3 (7%)
Lameness duration before treatment (no. (%))
1–6 months 35 (81%)
>6 months 8 (19%)
Previous anti-osteoarthritic therapy
Yes 37 (86%)
No 6 (14%)
Lameness grading at baseline (no. (%))
1 11 (26%)
2 14 (32%)
3 15 (35%)
4 3 (7%)
Joint effusion grading at baseline (no. (%))
0 3 (7%)
1 10 (23%)
2 18 (42%)
3 7 (16%)
4 5 (12%)
Joint effusion grading at 24 months (no. (%))
0 31 (77.5%)
1 8 (20%)
2 0 (0%)
3 1 (2.5%)
4 0 (0%)
Table 2 Description of the study population of 43 horses
with osteoarthritis of a metacarpo(tarso)phalangeal joint
or carpal joint treated by intra-articular administration of
a polyacrylamide hydrogel and variables evaluated
during a 24 months follow-up (Continued)
Radiographic grading of OA at baseline (no. (%))
1 (mild) 23 (53%)
2 (moderate) 9 (21%)
3 (marked) 11 (26%)
Proportion of non-lame horses at (%)
1 month 60%
3 months 67%
6 months 79%
12 months 81%
24 months 82.5%
Owner satisfaction at 24 months (%)
Not satisfied 2.5%
Slightly satisfied 7.5%
Satisfied 15%
Very satisfied 75%
OA: osteoarthritis.
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of the horses respectively, retained the lameness grade at
the following lameness evaluation.
At baseline, joint effusion grade was 0 (7%), 1 (23%), 2
(42%), 3 (16%) and 4 (12%), whereas at 24 months joint
effusion grade was 0 (77.5%), 1 (20%), 2 (0%), 3 (2.5%)
and 4 (0%). No adverse effects associated with the
treated joints were detected during the study period.
At 24 months, 90% of the owners were satisfied or
highly satisfied with the outcome of the treatment,
whereas 10% of the owners were slightly satisfied or not
satisfied with the outcome of the treatment.
The statistical analysis showed a highly significant re-
duction of the lameness grade (all grades) after baseline
(P < 0.0001), and a highly significant association between
lameness grade and joint effusion (P < 0.0001). Estimates
for the odds ratios (OR) showed that OR for lower lame-
ness from month 1 to month 24 relative to baseline in-
creased from 20 (95% CI = 6–67) to 58 (95% CI = 12–
275) (Table 3). These confidence intervals for OR were
wide; however, they were clearly bounded away from 1,
which was also reflected by the p-value. Thus, there was
a highly significant effect. OR for lower lameness grade
was 3.1 (95% CI = 2.0-4.9) when joint effusion decreased
by one grade (Table 3).
Estimates for OR showed that joint effusion score de-
creased significantly over time (P < 0.0001), and decreased
significantly with radiography scoring (P = 0.0041) (Table 4):
OR for lower joint effusion grade from month 1 to month
24 relative to baseline increased from 13 (95% CI = 5–34)
Figure 1 Distribution of lameness grades at baseline and at 1, 3, 6, 12 and 24 months following the treatment with PAAG. Error bars show
standard errors of the estimated proportions within each time group. The left most bars in each time group correspond to non-lame horses.
There was a significant increase in the proportion of non-lame horses between baseline and 1 month, followed by a steady increase between 3
and 6 months, then a stabilization in the proportion of non-lame horses between 6 and 24 months.
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OR were wide; however, they were clearly bounded away
from 1, which was also reflected by the p-value. OR for
lower joint effusion scoring was 3.1 (95% CI = 1.9-5.1)
when radiographic grade at baseline was low by one grade.
Discussion
This 2 year clinical study demonstrated that PAAG sig-
nificantly alleviated lameness in osteoarthritic joints, as
assessed by clinical lameness evaluation. A similar out-
come was found in a recent pilot randomized controlled
study on an experimental OA model in goats, where
75% (3 out of 4) of goats treated with PAAG were non-
lame 4 months after the treatment [18]. No adverse ef-
fects were observed during the study period in the
treated joints, which is consistent with previous studiesFigure 2 Distribution of change of lameness grades of individual horses o
estimated proportions within each time period. The middle bars with shad
over the designated time period. The largest reduction in lameness took pusing PAAG intra-articularly to treat equine OA
[16,17,19,20]. PAAG has also proven to be safe in
humans for more than 15 years of use [12-14].
The statistical analysis showed a highly significant (P <
0.0001) reduction of the lameness grade after baseline.
The estimated OR showed an increased reduction over
time from OR = 20 from baseline to month 1 to OR = 58
from baseline to month 24. The largest reduction in
lameness grade appeared from baseline to month 1.
After month 1 the lameness grade continued to de-
crease, although the difference between months 1, 3, 6,
12 and 24 was non-significant (p = 0.18). In particular,
the OR was very constant from months 6 to 24. Thus,
the clinical improvement in lameness grade was already
present one month after PAAG treatment. This suggests
that the effect of PAAG on OA might occur mainlyver consecutive time points. Error bars show standard errors of the
ing lines correspond to horses that have retained their lameness score
lace at 1 month follow-up.
Table 3 Estimated odds ratios for lower lameness grade
between time points and differences in joint effusion and
associated 95% confidence intervals
Odds ratio Estimate 95% confidence limits
Month 1 vs Baseline 20.45 6.24 66.98
Month 3 vs Baseline 23.16 5.65 94.85
Month 6 vs Baseline 50.94 12.29 211.05
Month 12 vs Baseline 66.64 15.46 287.14
Month 24 vs Baseline 57.71 12.12 274.71
Effusion −1 3.12 1.97 4.94
Odds ratios for lower lameness from month 1 to month 24 relative to baseline
increased from 20 (95% CI = 6–67) to 58 (95% CI = 12–275).
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creases progressively until 6 months, with a stabilization
between 6 and 24 months.
Worsening of the lameness grade following a previous
lameness improvement was observed in only 3 horses
with baseline lameness grade 1 (n = 3/11). Since no
radiographic follow-up was performed in our clinical
trial, it is difficult to speculate on the reason of lameness
worsening in these horses. None of the horses with base-
line lameness grade 2, 3 or 4 showed deterioration in
lameness.
This clinical study has also demonstrated that joint ef-
fusion grade decreased significantly over time (P <
0.0001). At baseline, joint effusion was absent in only 7%
of the horses, while at 24 months the majority of horses
(77.5%) showed no joint effusion of the treated joints.
Since lameness grade decreased significantly (P < 0.0001)
with lower effusion grade, part of the lameness improve-
ment over time can be seen through lowering of the
joint effusion.
Although joint effusion was subjectively assessed in
this study, PAAG induced a significant decrease in joint
effusion in the osteoarthritic joints. However, theTable 4 Estimated odds ratios for lower joint effusion
grade between time points and differences in
radiography grade at baseline and associated 95%
confidence intervals
Odds ratio Estimate 95% confidence limits
Month 1 vs Baseline 13.21 5.14 33.96
Month 3 vs Baseline 38.18 11.72 124.40
Month 6 vs Baseline 106.14 32.31 348.61
Month 12 vs Baseline 91.52 28.19 297.07
Month 24 vs Baseline 171.80 46.35 636.76
Radiography grade −1 3.12 1.90 5.13
OR for lower joint effusion grade from month 1 to month 24 relative to
baseline increased from 13 (95% CI = 5–34) to 172 (95% CI = 46–637). OR for
lower joint effusion grade was 3.1 (95% CI = 1.9-5.1) when radiographic grade
at baseline was low by one grade.mechanism-of-action of PAAG in reducing joint effusion
in osteoarthritic joints needs to be investigated.
The majority of horses (86%) had received a previous un-
successful anti-osteoarthritic treatment, before receiving
PAAG, but there was no correlation between the previous
treatment and the outcome lameness variable. In some
cases (14%), which were mainly among the last included
cases, PAAG was used as a first line treatment based on the
encouraging results of the first cases of the study.
At 24 months, 90% of the owners were either satisfied
or very satisfied with the outcome of this new OA treat-
ment. This is consistent with the outcome as assessed by
the veterinary clinicians (82.5% of non-lame horses at
24 months).
Although conventional concepts of OA emphasize the
direct and predominant involvement of cartilage and
bone in OA development, it is increasingly recognized
that the synovium also contributes to the central patho-
physiological event of cartilage matrix depletion. Lack of
joint lubrication is postulated to play a significant role in
the pathogenesis of OA [24]. This emphasizes the role of
viscosupplementation, and hence the improvement of
lubrication within the joint, in protecting a joint suffer-
ing from OA, and reducing the resulting pain. Recently,
a study supported the use of intra-articular lubricin as
an adjunct to viscosupplementation for retarding cartil-
age degeneration and possibly the development of post-
traumatic OA [25,26].
Precise characterization of the mechanism-of-action of
PAAG on osteoarthritic joints has not yet been estab-
lished, but histopathological observations on joint tissue
from horses [Christensen L, personal communication]
and goats [18] have demonstrated that PAAG, like in
other soft tissues, becomes integrated within the synovial
membrane.
In the goat study [18], the synovial membrane of the
joints injected with PAAG had a better elastance when
compared to the synovial membrane of the control
joints. Osteoarthritic joints typically show joint stiffness
which is a major source of pain in OA. This is supported
by a recent study on human knee joint stiffness, which
showed that the stiffness co-efficient was higher in indi-
viduals with painful OA compared to those with normal
knees [27].
By integrating the synovial membrane, which may
probably decrease the joint capsule stiffness and hence
the joint stiffness, PAAG might relieve pain of the osteo-
arthritic joint. This theory is supported by clinical obser-
vations in the study population where osteoarthritic
joints that responded well to PAAG were no more pain-
ful to passive manipulation of the joints.
The inclusion criteria in the present study were strict
in order to maximize the validity of the results. Never-
theless, there were some study limitations including a
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non controlled clinical study, and the subjective assess-
ment of joint distension. A quantitative measurement of
joint circumference could have been performed. This
was a multi-centre study, which represented another
study limitation due to several clinicians involved in the
study, and the potential for inconsistency in application
of the lameness grading scale among the clinicians and
within clinicians at different examinations [28]. In
addition, radiography was not used for the follow-up of
OA because of its association with a series of concerns
including the insensitivity of radiographs to detect early
and small changes and the slow progression of OA being
a common finding in clinical trials [5]. Repeatability of
application of the radiographic grading system was not
assessed.
The present study has shown that PAAG relieved or
completely removed the symptoms of lameness and the
joint distention in osteoarthritic joints and can be con-
sidered as a disease-modifying OA therapeutic agent. A
recent study on an OA model in goats [18] has shown
that PAAG reduces the progression of OA as evaluated
by MRI and histopathology, which supports the hypoth-
esis that PAAG contributes to a disease-stabilizing affect.
Further work investigating the mechanism of action of
PAAG in osteoarthritic joints is required.
Conclusions
PAAG significantly alleviated lameness and joint effusion
in osteoarthritic joints in horses. PAAG is a promising,
safe and lasting (at least 24 months) new treatment for
OA in horses and its further evaluation is warranted.
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